The U.S. clinical trials market size was exhibited at USD 41.19 billion in 2024 and is projected to hit around USD 75.95 billion by 2034, growing at a CAGR of 6.31% during the forecast period 2024 to 2034.
The U.S. clinical trials market growth is attributed to the rising applications and adoption of advanced technologies in clinical studies, increased healthcare expenditure, outsourcing through pharmaceutical CDMOs (Contract Development and Manufacturing Organizations) and the surge in investments from public and private sectors for conduction of research and development of innovative therapies and treatments through clinical trials. Furthermore, the utilisation of digital tools such as digital biomarkers for real-time patient monitoring and increased patient focus towards telemedicine has accelerated the conduction and participant engagement in decentralized clinical trials.
The increase in number of registration cohorts for clinical trials is trending in the U.S. due to rising public awareness about importance of clinical trials for developing new treatments for chronic diseases with improved safety, accuracy and biocompatibility thereby enhancing patient life outcomes. Moreover, growing focus on patient-centric approach and rising rates of chronic diseases and disorders is driving the market growth. However, addressing issues such as representation of minor communities, geographical discrepancies and consideration of socioeconomic factors can potentially escalate the clinical trial participation rates.
Patient preference towards personalized medicine over the conventional treatment methods, advancements in genetic testing and digitalization of patient records by using Electronic Data Capture (EDC) systems is enabling researchers to utilise clinical data conveniently for developing potential cures. Furthermore, the access to clinical trials data and sources through readily available national databases and online platforms is assisting individuals in staying informed about the ongoing developments in clinical trials.
Various initiatives and platforms implemented by government healthcare institutes in the U.S. is encouraging data collection, monitoring of changes in patient trends, health communication and information technology. The Health Information National Trends Survey (HINTS) created by the National Cancer Institute (NCI) regularly monitors and collects nationally representative data of America’s swiftly progressing health communication field and also provides insights on the clinical trial participation. Furthermore, the influence of the Food and Drug Administration (FDA) on implementing strict guidelines and for approving the conduction of trials as well as accelerating applications of new drugs, treatments and medical devices for enhancing safety and care is boosting the development of preclinical and clinical studies along with the development of late stage clinical trials.
Growing focus and research on burgeoning areas such as gene therapies and technologies, immunotherapies, biosimilars, precision medicine, implementation of bioinformatics tools and development of strong product pipelines are driving new clinical trial applications.
Technological advancements empowering the incorporation of artificial intelligence (AI) and machine learning tools for designing of clinical trials, patient recruitment, predictive modelling and streamlining data analysis is strengthening the development of faster and more targeted clinical trials. The recent development of an AI algorithm called TrialGPT by researchers from the National Institute of Health (NIH) is speeding up the process of identifying potential volunteers pertinent to clinical research trials which improves clinical trial enrolment.
Clinical trials are an essential medium of evaluating new treatments for advancing patient care. Inadequate rise in clinical trials leads to premature closing, resource wastage, lost chances for advancements and decrease in public trust. Furthermore, various structural, clinical, attitudinal and socioeconomic factors are affecting clinical trial participation. The initiatives for promoting clinical trial invitation and participation, development of structural solutions for expanding accessibility and availability of trials, increasing clinical trials awareness through educational campaigns and deployment of trained staff for recruitment of target population and data analysis is creating opportunities for boosting the transformation of U.S. clinical trials market.
Published by Ajit Bansod
